Sangamo Therapeutics (SGMO) News Today $2.47 +0.16 (+6.93%) (As of 12/20/2024 05:40 PM ET) Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 February 2022 January 2022 Time Period Sangamo Biosciences: Strategic Neurology Advancements and Financial Growth Potential with Astellas PartnershipDecember 20 at 7:41 PM | markets.businessinsider.comSangamo: Pipeline Expansion Via Partnership And Internal ST-503 DevelopmentDecember 19 at 3:04 PM | seekingalpha.comHC Wainwright Reiterates Buy Rating for Sangamo Therapeutics (NASDAQ:SGMO)HC Wainwright reaffirmed a "buy" rating and set a $10.00 target price on shares of Sangamo Therapeutics in a report on Thursday.December 19 at 11:55 AM | marketbeat.comSangamo Therapeutics (NASDAQ:SGMO) Shares Gap Up - Here's What HappenedSangamo Therapeutics (NASDAQ:SGMO) Shares Gap Up - Still a Buy?December 19 at 11:02 AM | marketbeat.comSangamo Shares Rally Premarket on License Deal With AstellasDecember 19 at 10:03 AM | marketwatch.comWhy Sangamo Therapeutics Shares Are Trading Higher By Around 20%; Here Are 20 Stocks Moving PremarketDecember 19 at 10:03 AM | benzinga.comAstellas and Sangamo Therapeutics Announce Capsid License Agreement to Deliver Genomic Medicines for Neurological DiseasesDecember 19 at 2:30 AM | prnewswire.comSangamo Therapeutics (NASDAQ:SGMO) Shares Down 5% - Time to Sell?Sangamo Therapeutics (NASDAQ:SGMO) Shares Down 5% - Time to Sell?December 18 at 2:20 PM | marketbeat.comSangamo Therapeutics (NASDAQ:SGMO) Shares Gap Down - Time to Sell?Sangamo Therapeutics (NASDAQ:SGMO) Shares Gap Down - Should You Sell?December 17, 2024 | marketbeat.comSangamo Therapeutics (NASDAQ:SGMO) Stock Rating Upgraded by StockNews.comStockNews.com upgraded Sangamo Therapeutics from a "hold" rating to a "buy" rating in a research note on Monday.December 16, 2024 | marketbeat.comSangamo Therapeutics (NASDAQ:SGMO) Stock Price Up 25.5% - Here's What HappenedSangamo Therapeutics (NASDAQ:SGMO) Stock Price Up 25.5% - What's Next?December 16, 2024 | marketbeat.comSangamo Therapeutics (NASDAQ:SGMO) Raised to "Buy" at Truist FinancialDecember 15, 2024 | americanbankingnews.comSangamo Biosciences: Strategic Growth and Advancing Pipeline Drive Buy RatingDecember 14, 2024 | markets.businessinsider.comTD Cowen Sticks to Their Buy Rating for Sangamo Biosciences (SGMO)December 14, 2024 | markets.businessinsider.comSangamo Therapeutics (NASDAQ:SGMO) Stock Rating Upgraded by Truist FinancialTruist Financial raised Sangamo Therapeutics from a "hold" rating to a "buy" rating and set a $7.00 price target on the stock in a report on Friday.December 13, 2024 | marketbeat.comSangamo Therapeutics (NASDAQ:SGMO) Receives Buy Rating from HC WainwrightDecember 13, 2024 | americanbankingnews.comSangamo Biosciences’ Legal Victory and Hemophilia Trial SuccessDecember 11, 2024 | markets.businessinsider.comPromising Trial Results and Strategic Partnerships Drive Buy Rating for Sangamo BiosciencesDecember 11, 2024 | markets.businessinsider.comThe Analyst Landscape: 6 Takes On Sangamo TherapeuticsDecember 11, 2024 | benzinga.comJacobs Levy Equity Management Inc. Lowers Holdings in Sangamo Therapeutics, Inc. (NASDAQ:SGMO)Jacobs Levy Equity Management Inc. reduced its stake in shares of Sangamo Therapeutics, Inc. (NASDAQ:SGMO - Free Report) by 50.1% in the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 1,471,7December 9, 2024 | marketbeat.comSangamo Therapeutics (NASDAQ:SGMO) Downgraded by StockNews.com to "Hold"StockNews.com lowered Sangamo Therapeutics from a "buy" rating to a "hold" rating in a report on Friday.December 6, 2024 | marketbeat.comWasatch Advisors LP Sells 648,202 Shares of Sangamo Therapeutics, Inc. (NASDAQ:SGMO)Wasatch Advisors LP decreased its position in shares of Sangamo Therapeutics, Inc. (NASDAQ:SGMO - Free Report) by 3.2% during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 19,442,368 shares of the biopharmaceutical company's sDecember 1, 2024 | marketbeat.comSangamo Therapeutics, Inc. (NASDAQ:SGMO) Short Interest UpdateSangamo Therapeutics, Inc. (NASDAQ:SGMO - Get Free Report) saw a large decline in short interest in the month of November. As of November 15th, there was short interest totalling 13,390,000 shares, a decline of 29.5% from the October 31st total of 18,980,000 shares. Based on an average daily trading volume, of 7,230,000 shares, the short-interest ratio is presently 1.9 days.November 29, 2024 | marketbeat.comGSA Capital Partners LLP Trims Stock Holdings in Sangamo Therapeutics, Inc. (NASDAQ:SGMO)GSA Capital Partners LLP reduced its position in Sangamo Therapeutics, Inc. (NASDAQ:SGMO - Free Report) by 63.0% in the third quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 345,632 shares of the biopharmaceutical company's stock after seNovember 23, 2024 | marketbeat.comSangamo gets FDA clearance of IND application for ST-503 in iSFNNovember 21, 2024 | markets.businessinsider.comSangamo stock climbs 12% post-market on FDA update for ST-503November 21, 2024 | msn.comResearch Analysts Set Expectations for SGMO FY2024 EarningsSangamo Therapeutics, Inc. (NASDAQ:SGMO - Free Report) - Analysts at HC Wainwright decreased their FY2024 earnings per share estimates for Sangamo Therapeutics in a research report issued on Thursday, November 14th. HC Wainwright analyst P. Trucchio now expects that the biopharmaceutical companyNovember 18, 2024 | marketbeat.comHC Wainwright Has Bullish Outlook for SGMO FY2028 EarningsSangamo Therapeutics, Inc. (NASDAQ:SGMO - Free Report) - Equities researchers at HC Wainwright increased their FY2028 earnings per share (EPS) estimates for Sangamo Therapeutics in a report released on Thursday, November 14th. HC Wainwright analyst P. Trucchio now anticipates that the biopharmaceNovember 15, 2024 | marketbeat.comWells Fargo Gives a Hold Rating to Sangamo Biosciences (SGMO)November 15, 2024 | markets.businessinsider.comBarclays Raises Sangamo Therapeutics (NASDAQ:SGMO) Price Target to $9.00Barclays boosted their target price on Sangamo Therapeutics from $3.00 to $9.00 and gave the company an "overweight" rating in a research note on Thursday.November 14, 2024 | marketbeat.comSangamo Biosciences: Promising Financial Position and Strategic FDA Alignment Drive Buy RatingNovember 14, 2024 | markets.businessinsider.comQ3 2024 Sangamo Therapeutics Inc Earnings CallNovember 13, 2024 | uk.finance.yahoo.comRBC Capital Remains a Hold on Sangamo Biosciences (SGMO)November 13, 2024 | markets.businessinsider.comSangamo Therapeutics Reports Recent Business Highlights and Third Quarter 2024 Financial ResultsNovember 13, 2024 | finanznachrichten.deSangamo options imply 21.0% move in share price post-earningsNovember 13, 2024 | markets.businessinsider.comSangamo Therapeutics Reports Strong Q3 2024 GrowthNovember 13, 2024 | markets.businessinsider.comSangamo Therapeutics Inc (SGMO) Q3 2024 Earnings Call Highlights: Strategic Advances and ...November 13, 2024 | finance.yahoo.comSangamo Therapeutics, Inc. (SGMO) Q3 2024 Earnings Call TranscriptNovember 12, 2024 | seekingalpha.comEquities Analysts Set Expectations for SGMO FY2024 EarningsSangamo Therapeutics, Inc. (NASDAQ:SGMO - Free Report) - Analysts at HC Wainwright reduced their FY2024 earnings per share (EPS) estimates for shares of Sangamo Therapeutics in a report released on Tuesday, November 5th. HC Wainwright analyst P. Trucchio now anticipates that the biopharmaceuticalNovember 7, 2024 | marketbeat.comSangamo options imply 14.5% move in share price post-earningsNovember 6, 2024 | markets.businessinsider.comSangamo price target raised to $10 from $5 at H.C. WainwrightNovember 6, 2024 | markets.businessinsider.comSangamo Therapeutics (SGMO) Set to Announce Quarterly Earnings on TuesdaySangamo Therapeutics (NASDAQ:SGMO) will be releasing earnings after the market closes on Tuesday, November 12, Zacks reports.November 5, 2024 | marketbeat.comHC Wainwright Forecasts Strong Price Appreciation for Sangamo Therapeutics (NASDAQ:SGMO) StockHC Wainwright upped their price target on Sangamo Therapeutics from $5.00 to $10.00 and gave the stock a "buy" rating in a research note on Tuesday.November 5, 2024 | marketbeat.comSangamo Therapeutics Announces Third Quarter 2024 Conference Call and WebcastNovember 4, 2024 | finance.yahoo.comSangamo Therapeutics (NASDAQ:SGMO) Stock Crosses Above 200 Day Moving Average - Here's WhySangamo Therapeutics (NASDAQ:SGMO) Stock Price Crosses Above 200 Day Moving Average - Here's What HappenedNovember 1, 2024 | marketbeat.comTruist Financial Keeps Their Hold Rating on Sangamo Biosciences (SGMO)October 24, 2024 | markets.businessinsider.comSangamo Biosciences (SGMO) Gets a Buy from TD CowenOctober 24, 2024 | markets.businessinsider.comSangamo Therapeutics Shares Jump After FDA Discussion on Accelerated Approval Pathway for Fabry Disease DrugOctober 23, 2024 | marketwatch.comWhat's Going On With Sangamo Therapeutics Shares Tuesday?October 23, 2024 | msn.comSangamo Therapeutics (NASDAQ:SGMO) Stock Rating Reaffirmed by HC WainwrightHC Wainwright reissued a "buy" rating and issued a $5.00 price target on shares of Sangamo Therapeutics in a research report on Tuesday.October 22, 2024 | marketbeat.com Get Sangamo Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for SGMO and its competitors with MarketBeat's FREE daily newsletter. Email Address Crypto’s hidden gem + greatest crypto bull run in history = $$$? (Ad)You don’t actually want to buy Bitcoin this time around. That’s because there’s a better way to take advantage of this new bull market… One market expert calls it Crypto’s Hidden Gem And it’s a new way that has given folks like you and me the chance to see bigger and faster moves than the traditional way of buying Bitcoin… That means if you’ve stayed away from Bitcoin and crypto because it's confusing or seems risky… This is a much safer and better approach to ride this years’ crypto bull run. Because believe it or not… The 2024 crypto bull run is one you DON’T want to miss. Click Here to get the full details about Crypto’s Hidden Gem SGMO Media Mentions By Week SGMO Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. SGMO News Sentiment▼0.440.59▲Average Medical News Sentiment SGMO News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. SGMO Articles This Week▼132▲SGMO Articles Average Week Get Sangamo Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for SGMO and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies MNKD News CLDX News DVAX News BCRX News NVAX News MYGN News INVA News OPK News IRWD News EBS News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:SGMO) was last updated on 12/21/2024 by MarketBeat.com Staff From Our PartnersAmazon coin set to soar 25X – starting December 16th?This tiny 3-cent crypto just partnered with one of the biggest companies in the world… Amazon. And one team...True Market Insiders | SponsoredDid You See Trump’s Bombshell Exec. Order 001?Biden broke it... Now Trump is going to fix it. Starting with "Exec. Order 001."Banyan Hill Publishing | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredThe #1 Crypto for AIWe’ve issued an urgent landmark trade alert for a new crypto wonder. So, I decided to give you this heads-u...Weiss Ratings | SponsoredVideo: Blindfolded Man Gets Into a Cybertruck… What Happens Next Will Shock You“Hi, I’m Jeff Brown… Even though I can’t see a thing… I’m about to get in this Cybertruck and drive up t...Brownstone Research | SponsoredTrump’s Sending THIS Crypto Higher on PurposeDiscover the coin set to explode before 2025! Trump could trigger THIS crypto coin… Crypto 101 Media | SponsoredElon Musk’s chilling warning for humanityThe 'invasion' I've discovered has nothing to do with the border crisis. What's happening at our southern bord...The Freeport Society | SponsoredVladimir Lenin was right…The Magnificent 7 could be in for a world of pain… And the insiders know it. It’s why Jeff Bezos just sold ...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Sangamo Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Sangamo Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
